AchieveRx Reports Third Quarter 2026 Financial Results and Provides Business Updates
Globe Newswire•10/11/2026•08:00 ET
0
Key Highlights
- ➤Cash, equivalents, and marketable securities reached $201.5 million September 30, 2026
- ➤ORCA-OL four-week continuous abstinence rose to 31.2% at Weeks 49–52
- ➤NDA resubmission remains on track for the fourth quarter of 2026
- ➤Net loss reached $12.1 million in the third quarter of 2026
- ➤AchieveRx completed three commercial-scale stability batches at Adare’s U.S. facility
Expert Statements
Andrew D. Goldberg, MD, Chief Executive Officer, AchieveRx
“Becoming AchieveRx, The Quit Company, reflects our shift from a clinical-stage company to one preparing to launch what could be the first new FDA-approved prescription medicine in 20 years to help people who smoke quit”
Andrew D. Goldberg, MD, Chief Executive Officer, AchieveRx
“Our 52-week ORCA-OL results add to the growing body of evidence supporting cytisinicline as a potential treatment option for people looking to quit smoking. With an experienced launch team and our NDA resubmission on track for later this year, we are well positioned to bring cytisinicline to people who want to quit, if it is approved.”
Ben Halladay, Chief Financial Officer, AchieveRx
“The opportunity ahead of us is large, and so is our duty to fund it well”
Ben Halladay, Chief Financial Officer, AchieveRx
“We’re entering this next phase with a strong balance sheet, and my priority is disciplined capital allocation that supports both our NDA resubmission and readiness for a potential U.S. launch in 2027.”
Launched new corporate brand as AchieveRx, The Quit Company (Nasdaq: QUIT)
Presented 52-week ORCA-OL data at the CHEST 2026 Annual Meeting showing that nearly one in three adults still smoking or vaping after a supervised quit attempt in a prior trial (a median of five quit attempts among those who smoked) had quit by the end of treatment, with quit rates rising over the course of the year
Get started
Create a free account to read the full story.